Ronit Dutta, Madhumathi Subramanian, Karpagavalli Subramanian and Krishna Shah*

Optometrist, Department of Contact Lens, Sankara Nethralaya, Unit of Medical Research Foundation, Chennai, Tamil Nadu, India

*Corresponding Author: Krishna Shah, Optometrist, Department of Contact Lens, Sankara Nethralaya, Unit of Medical Research Foundation, Chennai, Tamil Nadu, India.

Received: June 30, 2025; Published: July 31, 2025

Abstract

Introduction: Ptosis is drooping of the upper eyelid which can be neurological, myogenic, traumatic, mechanical, or progressive exopthalmoplegia. Ptosis correction is sometimes challenging possibly due to its progressive nature. This case report emphasizes the other dimension of Scleral fitting the patient. The case report enlightens the importance of scleral lenses for improving cosmesis in eyes with ptosis.

Case: This case series reports 3 cases of ptosis managed with scleral lenses. Firstly, a 50-year-old male complained of drooping of the right eye and poor visual quality for distant objects. The patient’s previous ocular history reports that he underwent Laser vision correction in both eyes and ptosis correction in the right eye. The palpebral fissure height with scleral lenses increased to 11 mm with scleral lenses which was 10 mm at baseline measurement. Similarly, the second case is of a patient was 65 years old lady who had unilateral ptosis which was managed with a scleral lens. The palpebral fissure height increased to 7 mm with scleral lenses which was 0 mm previously. Lastly, a 35-year-old male patient was diagnosed with Steven Jhonson syndrome and has blepharoptosis in the right eye. Scleral lenses were tried with which the PFH improved to 8 mm from 4 mm.

Conclusion: The case report underscores the potential utility of scleral lens as a noninvasive option for ptosis management particularly in cases where surgical intervention may not be desirable or feasible. The scleral lens offers an innovative approach to address both the aesthetic and functional aspects and ultimately improve the quality of life.

Keywords: Ptosis; Scleral Lens; Dry eye, Ptosis Management; PROSE Lenses; Blepharoptosis

References

1. Miller JJ., et al. “Progress in the understanding and treatment of Fabry disease”. Biochimica et Biophysica Acta (BBA) - General Subjects1 (2020): 129437.
2. Raj A., et al. “Fabry disease management: Current status, therapeutic challenges, and future horizons in drug delivery and artificial intelligence assisted diagnosis”. Journal of Drug Delivery Science and Technology 100 (2024): 106032-106032.
3. Weissman D., et al. “Fabry Disease: Cardiac Implications and Molecular Mechanisms. Current Heart Failure Reports2 (2024): 81-100.
4. Palaiodimou L., et al. “Fabry Disease: current and novel therapeutic strategies. A narrative review”. Current Neuropharmacology (2022): 20.
5. Päivi Pietilä‐, et al. “Long‐term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study”. American Journal of Medical Genetics. Part A 191.7 (2023): 1858-1869.
6. Yoo H. “Fabry disease: current treatment and future perspective”. Journal of Genetic Medicine1 (2023): 6-14.
7. Nowicki M., et al. “A review and recommendations for oral chaperone therapy in adult patients with Fabry disease”. Orphanet Journal of Rare Diseases1 (2024).
8. Go.drugbank.com (2024).
9. Migalastat. Nih.gov; PubChem (2025).
10. Canadian Agency for Drugs and Technologies in Health. Executive Summary. Nih.gov; Canadian Agency for Drugs and Technologies in Health (2018).
11. Migalastat Side Effects: Common, Severe, Long Term. Drugs.com (2024).
12. Germain D P., et al. “Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat”. New England Journal of Medicine6 (2016): 545-555.
13. Kugadas A., et al. “Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients”. PLOS ONE5 (2024): e0304415.
14. Malte Lenders., et al. “Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease”. Orphanet Journal of Rare Diseases1 (2025).
15. New drug: Migalastat for Fabry disease. Australian Prescriber 42.1 (2018): 29.

Citation

Citation: Krishna Shah., et al. “Scleral Lens - An Approach to Aesthetic Improvement in Ptosis - A Case Report".Acta Scientific Ophthalmology 8.8 (2025): 16-19.

Copyright

Copyright: © 2025 Krishna Shah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.